Axsome Therapeutics/$AXSM
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
- Ticker
- $AXSM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,346
- Headquarters
- New York, United States
- Website
- www.axsome.com
AXSM Metrics
BasicAdvanced
$11B
-
-$3.76
0.73
-
Price and volume
Market cap
$11B
Beta
0.73
52-week high
$260.19
52-week low
$109.60
Average daily volume
719K
Financial strength
Current ratio
1.426
Quick ratio
1.297
Long term debt to equity
178.337
Total debt to equity
263.142
Interest coverage (TTM)
-14.20%
Profitability
EBITDA (TTM)
-172.919
Gross margin (TTM)
93.24%
Net profit margin (TTM)
-24.68%
Operating margin (TTM)
-23.55%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
-16.31%
Return on equity (TTM)
-245.10%
Valuation
Price to revenue (TTM)
14.142
Price to book
135.41
Price to tangible book (TTM)
332.72
Price to free cash flow (TTM)
-152.623
Free cash flow yield (TTM)
-0.66%
Free cash flow per share (TTM)
-1.413
Growth
Revenue change (TTM)
56.87%
Earnings per share change (TTM)
-25.68%
3-year revenue growth (CAGR)
62.05%
3-year earnings per share growth (CAGR)
-4.19%
10-year earnings per share growth (CAGR)
11.29%
What the Analysts think about AXSM
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
AXSM Financial Performance
Revenues and expenses
AXSM Earnings Performance
Company profitability
AXSM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.